Sign in
Not yet taking people in United StatesPhase 2

A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

Key facts

Who runs it
Afasci Inc
Where
Los Angeles, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
36 people, planned
Started
1 Oct 2025
Expected to end
1 Dec 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • AFA-281
Record updated
29 November 2024

Who can take part

Age
21 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Age between 21 and 65
  • Must voluntarily sign and date each informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures
  • Meet current (i.e., past 12 months) DSM-5 diagnostic criteria for moderate or severe AUD
  • Report drinking at least 28 drinks per week if male, 21 drinks per week if female, in the 28 days prior to consent
  • Must be surgically sterile (vasectomy, tubal ligation, or hysterectomy) or agree to be sexually inactive or agree to use a barrier method of birth control (i.e., condom) from the start of screening until study completion, and agree to refrain from donating sperm for 90 days after study drug administration

Who cannot take part

  • Current treatment for alcohol use or a history of treatment in the 30 days before enrollment or treatment seeking
  • Positive urine drug screen for drugs of abuse at Screening or Day -1
  • Receipt of any drug by injection within 30 days prior to study drug administration
  • Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration
  • Receipt of any investigational products within 6 weeks prior to study drug administration
  • Previous enrollment in this study
  • Current DSM-5 diagnosis of substance use disorder for any substance other than alcohol and nicotine
  • Lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder
  • Current DSM-5 major depressive disorder with suicidal ideation
  • History of significant sensitivity to any drug
  • History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma), renal, hepatic, gastrointestinal, hematologic, endocrine, dermatological, metabolic or psychiatric disease or disorder, or any uncontrolled medical illness
  • History of head trauma with loss of consciousness, seizures or convulsions, including febrile, alcohol or drug withdrawal seizures
  • History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH, or absorption
  • Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or HIV antibodies (HIV Ab). Negative HIV status will be confirmed at Screening and the results will be maintained confidentially by the study site
  • A clinically notable vital sign abnormality including a history of syncopal or near syncopal events following abrupt change in posture
  • Has a clinically significant abnormal ECG or an ECG with a QTc interval corrected for heart rate using the Fridericia formula (QTcF) > 430 ms
  • Has an estimated creatinine clearance (CrCl) outside of normal range
  • Liver enzymes AST, ALT, or GGT ≥ 3 times upper normal limit
  • Current (last 12 months) DSM-5 diagnosis of dependence on any psychoactive substances other than nicotine
  • Positive urine screen for narcotics, amphetamines, or sedative hypnotics
  • Clinically significant alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised
  • Pregnancy, nursing, or refusal to use reliable method of birth control if female
  • Pregnant or nursing women
  • Current enrollment in another clinical study
  • Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to participate in the AFA-281 Phase I1a Study

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 65 years old?

Where in United States

  • University of CaliforniaLos Angeles, United StatesContact: Lara Ray, MDNot yet recruiting

About the trial

What the trial wants to find out

This study will evaluate the safety and exploratory efficacy of AFA-281 in patients with Alcohol use disorder on cravings, subjective response to alcohol, pain thresholds, anxiety, depression, and sleep.

The 3 groups in the trial

  • AFA-281 placebo controlPlacebo, for comparison

    AFA-281 placebo control group

    Treatment: AFA-281

  • Low dose of AFA-281Existing treatment, for comparison

    AFA-281 at 60 mg per day

    Treatment: AFA-281

  • High dose AFA-281Existing treatment, for comparison

    AFA-281 at 120 mg per day

    Treatment: AFA-281

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Double-blind, Placebo-controlled, Phase IIA Human Laboratory Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder
Criteria questions
Built from NCT06710431, who can take part
Record updated
29 November 2024